Big Pharma's Special Sauce

The health care industry's biggest conference just finished up, and the Fool's health care team was keeping close watch. While much of the interest was focused on biotech outfits big and small, the industry's titans -- the big pharmaceutical companies -- made some noise of their own.

Our health care bureau chief, Brenton Flynn, listened in on seven big pharmaceutical companies that made an appearance, and in the following video he discusses what appears to be an industrywide shift toward specialty medications. However, one giant in the sector isn't convinced it's the best strategy.

In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking, and as an added bonus, you'll receive a full year of free analyst updates as significant news hits. Simply click here now to claim your copy today.

The article Big Pharma's Special Sauce originally appeared on Fool.com.

Brenton Flynn owns shares of Sarepta Therapeutics. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.